Inclusion Criteria:

          1. Patients over 18

          2. Untreated and pretreated (no more than 1 treatment) patients with metastatic melanoma
             at stage unreseactable IIIb-IV, histologically confirmed, that show V600 type BRAF
             mutations. Patients eligible for Phase I may have been pretreated with the
             investigational study treatments.

          3. Patient with measurable disease by RECIST v 1.1

          4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 - 1

          5. Patients who have successfully completed all the secondary side effects to previous
             systemic therapy

          6. Patients with an appropriate hematologic, hepatic and renal functionality, assessed in
             the 7 days preceding the start of therapy, as well as:

               -  Absolute neutrophil count (ANC)> 1.5 X 109 / L

               -  Absolute platelet count > 100 X 109 / L

               -  Hemoglobin > 9 g/dl

               -  Serum creatinine < 1.5 times the normal maximum values or Creatinine Clearance >
                  50 mL/hr (Cockroft-Gault formula)

               -  Transaminase level (AST and ALT) < 2.5 times the normal maximum values

               -  Serum bilirubin < 1.5 times the normal maximum values

          7. Negative pregnancy test performed within 7 days before beginning therapy
             (premenopausal women)

          8. Patients of childbearing age (or with partners of childbearing age) must use effective
             contraception during therapy and for at least 6 months after the effective treatment

          9. Absence of any psychological, familiar or social condition that may affect compliance
             with study protocol and scheduled follow-up

         10. Dated and signed informed consent before any study procedure

        Exclusion Criteria:

          1. Presence of symptomatic brain metastases

          2. Previous malignant cancer during the 2 years preceding the signing of informed consent

          3. Investigational study treatment within 28 days or 5 half-lives, whichever is longer,
             preceding the first dose of study treatments in this study

          4. Pregnancy and/or breast feeding;

          5. Nausea and vomit refractory to therapy, malabsorption, external biliary shunt,
             previous bowel resection, which could impair an adequate absorption

          6. Any of these conditions occurring in the 6 months before the start of Vemurafenib
             therapy: heart attack, unstable angina and/or severe degree, congestive heart failure,
             cerebrovascular accident or transient ischemic attack, pulmonary embolism, arterial
             hypertension not adequately controlled

          7. History of atrial or ventricular arrhythmia, symptomatic> grade 2 (NCI CTCAE)

          8. Hystory of retinopathy

          9. Correct QT interval > 450msec to baseline history of congenital long QT syndrome

         10. Uncontrolled medical condition among which endocrine disorders (such as
             hypothyroidism, hyperthyroidism and diabetes mellitus)

         11. Other severe medical or psychiatric conditions or abnormalities of laboratory tests
             that may increase the risk associated with study participation or the assumption of
             Vemurafenib, or that may interfere with the interpretation of study results, which in
             the judgment of the Investigator can make the patient not eligible for the study

         12. Unwillingness to practice adequate contraception

         13. Prior systemic treatment with BRAFi or MEKi, or interferon alpha